Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results WHO Solidarity Trial Consortium New England journal of medicine 384 (6), 497-511, 2021 | 2730 | 2021 |
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients JC Holter, SE Pischke, E de Boer, A Lind, S Jenum, AR Holten, K Tonby, ... Proceedings of the National Academy of Sciences 117 (40), 25018-25025, 2020 | 340 | 2020 |
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 270 | 2022 |
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study E Azoulay, P Pickkers, M Soares, A Perner, J Rello, PR Bauer, ... Intensive care medicine 43, 1808-1819, 2017 | 202 | 2017 |
The role of complement in liver injury, regeneration, and transplantation EB Thorgersen, A Barratt‐Due, H Haugaa, M Harboe, SE Pischke, ... Hepatology 70 (2), 725-736, 2019 | 164 | 2019 |
Epidemiology and patterns of tracheostomy practice in patients with acute respiratory distress syndrome in ICUs across 50 countries T Abe, F Madotto, T Pham, I Nagata, M Uchida, N Tamiya, K Kurahashi, ... Critical care 22, 1-16, 2018 | 149 | 2018 |
Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial A Barratt-Due, IC Olsen, K Nezvalova-Henriksen, T Kåsine, ... Annals of internal medicine 174 (9), 1261-1269, 2021 | 132 | 2021 |
Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study JG Laffey, F Madotto, G Bellani, T Pham, E Fan, L Brochard, P Amin, ... The Lancet Respiratory Medicine 5 (8), 627-638, 2017 | 121 | 2017 |
Complement in clinical medicine: clinical trials, case reports and therapy monitoring D Ricklin, A Barratt-Due, TE Mollnes Elsevier, 2017 | 98 | 2017 |
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials A Amstutz, B Speich, F Mentré, CS Rueegg, D Belhadi, L Assoumou, ... The Lancet Respiratory Medicine 11 (5), 453-464, 2023 | 92 | 2023 |
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis MV Maddali, M Churpek, T Pham, E Rezoagli, H Zhuo, W Zhao, J He, ... The Lancet Respiratory Medicine 10 (4), 367-377, 2022 | 87 | 2022 |
CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs EB Thorgersen, BC Hellerud, EW Nielsen, A Barratt-Due, H Fure, ... The FASEB Journal 24 (3), 712, 2010 | 79 | 2010 |
Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice M Huber-Lang, A Barratt-Due, SE Pischke, Ø Sandanger, PH Nilsson, ... The Journal of Immunology 192 (11), 5324-5331, 2014 | 75 | 2014 |
Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases—C3 or C5 emerge together with CD14 as promising targets A Barratt-Due, SE Pischke, PH Nilsson, T Espevik, TE Mollnes Journal of Leucocyte Biology 101 (1), 193-204, 2017 | 71 | 2017 |
Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19 AH Aamodt, EA Høgestøl, TH Popperud, JC Holter, AM Dyrhol-Riise, ... Journal of neurology, 1-10, 2021 | 64 | 2021 |
Chimeric anti-CD14 IGG2/4 hybrid antibodies for therapeutic intervention in pig and human models of inflammation C Lau, KS Gunnarsen, LS Høydahl, JT Andersen, G Berntzen, A Pharo, ... The Journal of Immunology 191 (9), 4769-4777, 2013 | 63 | 2013 |
Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans A Barratt-Due, EB Thorgersen, JK Lindstad, A Pharo, O Lissina, ... The Journal of Immunology 187 (9), 4913-4919, 2011 | 62 | 2011 |
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome A Barratt-Due, Y Fløisand, HL Orrem, AK Kvam, PA Holme, G Bergseth, ... Rheumatology 55 (7), 1337-1339, 2016 | 61 | 2016 |
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura E Azoulay, PR Bauer, E Mariotte, L Russell, P Knoebl, I Martin-Loeches, ... Intensive care medicine 45, 1518-1539, 2019 | 59 | 2019 |
Combined inhibition of complement (C5) and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis A Barratt-Due, EB Thorgersen, K Egge, S Pischke, A Sokolov, ... The Journal of Immunology 191 (2), 819-827, 2013 | 57 | 2013 |